Behçet’s Disease Complicated with Thrombosis

A Report of 93 Chinese Cases

Xiuhua Wu, MD, Guohua Li, MD, Xinxian Huang, MD, Li Wang, MD, Wanli Liu, PhD, Yan Zhao, MD, and Wenjie Zheng, MD

Abstract: To investigate the clinical features of Behçet’s disease (BD) complicated with thrombosis.

Medical records of patients with BD at Peking Union Medical College Hospital from 1993 to 2013 were reviewed to identify thrombosis.

Of the 766 patients with BD, 93 patients (16 female and 77 male) developed thrombosis. The most common thrombosis was extremity vein thrombosis (86.0%), including deep vein thrombosis (n = 78) and superficial thrombophlebitis (n = 4). The other thrombosis types associated with BD in descending frequency of order were: vena cava thrombosis (30.1%), pulmonary thromboembolism (15.1%), cerebral venous thrombosis (CVT) (12.9%), intracardiac thrombosis (8.6%), Budd–Chiari syndrome (7.5%), and renal vein thrombosis (4.3%), etc. Venous thrombosis is more frequent than arterial thrombosis, and most of patients (94.6%) experienced multiple thrombosis. A male predominance of extremity vein thrombosis and positive pathergy test, and a female predominance of CVT and genital ulcers were noted. All of these patients exhibited active disease during the emergence of thrombotic events. After treating with glucocorticosteroids, immunosuppressants, and/or anticoagulants, the thrombosis resolved in 89 patients. Three patients died from aneurysm rupture, myocardial infarction and Budd–Chiari syndrome, respectively. One patient with septic shock discontinued therapy during follow-up.

INTRODUCTION

Behçet’s disease (BD) is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology and is associated with thrombogenicity. Vascular manifestations of BD, which consist of venous involvements (thrombosis, superficial phlebitis) and arterial involvements (aneurysm, stenosis, occlusion), have been added into the updated International Criteria for Behçet’s Disease (ICBD), since they are one of the major characteristics of BD. Thrombosis is the most frequent vascular manifestation in BD and an important factor of adverse prognosis. In this study, we retrospectively analyzed 93 Chinese BD patients complicated with thrombosis, to summarize the clinical features of thrombosis in BD patients of Han ethnicity.

PATIENTS AND METHODS

Patients

We retrospectively analyzed medical record of BD patients with thrombosis from the Peking Union Medical College Hospital between December 1993 and December 2013. All of these patients fulfilled both 1990 International Study Group BD criteria and new ICBD. The diagnosis of thrombosis was based on the clinical assessments and imaging techniques findings, including Doppler ultrasound, phlebography, computed tomography angiography, and/or magnetic resonance angiography, in accordance with the criteria. Cardiac cavity thrombosis was diagnosed with transthoracic echocardiography. We also collected the demographic data, the interval between onset of BD and initial thrombotic event, related clinical features, laboratory parameters, treatment, and outcome. BD disease activity during the emergence of thrombosis event was assessed according to the BD Current Activity Form 2006 (BDCAF2006) (http://www.behcet.ws/pdf/BehcetsDiseaseActivityForm.pdf).

The institutional review board of PUMCH approved the study. Because the study was based on a review of medical records that had been obtained for clinical purposes, the requirement for written informed consent was waived.
Statistical Analysis

Statistical analysis was carried out using SPSS 16.0 for Microsoft Windows. Numerical data and categorical data were expressed as mean ± SD (range) and percentage, respectively. The Mann–Whitney U test is used to compare differences between means. The comparisons of various categorical clinical manifestations between two groups were evaluated using Pearson chi-square or Fisher exact test (when there were expected frequencies <5). All probabilities were two-sided, with \( P < 0.05 \) considered statistically significant.

RESULTS

Patient Characteristics

A total of 93 BD patients (77 male, 16 female) developed thrombosis, which accounted for 12.1% of the 766 BD patients (472 male, 294 female) hospitalized. Vascular thrombosis occurred more often in male patients (16.3% vs 5.4%, \( P < 0.01 \)). Their ages at diagnosis of BD were 32 ± 11 years old (range: 16–66 years old) and their ages at first thrombotic events were 33 ± 10 years old (range: 15–66 years old). The interval between BD diagnosis and emergence of first thrombotic events was 0 to 15 years. Among the 93 BD patients with thrombosis, thrombosis developed after the diagnosis of BD in 30 patients. The median interval was 2 years (0.5–15 years). There were 12 patients who developed thrombosis prior to the diagnosis of BD with the average interval from 4 months to 4 years. BD was diagnosed concomitantly with thrombosis in 51 patients.

Types of Thrombosis

As shown in Table 1, the most common types of thrombosis were extremity vein thrombosis (n = 80, 86.0%), including deep vein thrombosis (DVT; n = 78) and superficial thrombophlebitis (n = 4). Lower extremity DVT was diagnosed in 69 patients (20 cases of left, 19 cases of right, and bilateral in 30 cases), while upper extremity DVT was found in 14 patients (5 cases of right, 3 cases of left, and 6 cases of bilateral). Other cases of thrombosis associated with BD in descending order of frequency were vena cava thrombosis (n = 28, 30.1%), 23 cases were in the inferior vena cava and 10 cases were in the superior vena cava), pulmonary thromboembolism (PTE; n = 14, 15.1%; 9 cases were accompanied with lower extremity DVT simultaneously), cerebral venous thrombosis (CVT; n = 12, 12.9%), intracardiac thrombosis (n = 8, 8.6%; 5 cases were only in the right cavity, 1 case was only in the left cavity, 2 cases were in both cavities of the heart, and 4 cases were accompanied by PTE). In addition, we found Budd–Chiari syndrome in 7 cases (7.5%), renal vein thrombosis in 4 cases (4.3%), lower extremity artery thrombosis in 3 cases (3.2%), superior mesenteric veins thrombosis in 2 cases (2.2%), and abdominal artery thrombosis, carotid artery aneurysm thrombosis, femoral aneurysm thrombosis, and abdominal aortic aneurysm thrombosis in 1 case each (1.1%).

Among these cases, venous thrombosis was more common than arterial involvement, and most of patients (88/93, 94.6%) had multiple sites of thrombosis. Sixteen cases were complicated with aneurysms (abdominal aortic aneurysms in 8 cases, lower extremity artery aneurysms in 5 cases, pulmonary artery aneurysms in 3 cases, and carotid aneurysms and subclavian artery aneurysms in 1 case each); 5 cases were accompanied with artery stenosis and occlusion.

Systemic Manifestations

Oral ulceration was present in all patients. Other common findings included genital ulcers in 68 cases (73.1%), skin lesions in 67 cases (72.0%), positive pathergy test in 46 cases (49.5%), ocular involvement in 26 cases (28.0%), arthritis in 10 cases (10.8%), gastrointestinal involvement in 9 cases (9.7%), non-thrombotic neurologic involvement in 6 cases (6.5%), non-thrombotic cardiac involvement in 5 cases (5.4%), and epididymitis/orchitis in 3 cases (3.2%).

Active BD was documented in all patients during thrombosis onset, with BDCAF2006 score 5.8 ± 2.0 (range: 3–9). The accompany symptoms of oral ulceration in 48 cases (51.6%), genital ulceration in 23 cases (24.7%), skin lesions in 38 cases (40.9%), positive pathergy test in 23 cases (24.7%), ocular involvement in 14 cases (15.1%), digestive ulceration in 7 cases (7.5%), arthritis in 4 cases (4.3%), neurologic involvement in 4 cases (4.3%), and epididymitis/orchitis in 2 cases (2.2%).

Gender-Specific Clinical Features

Patients were stratified by gender. Male patients showed more predominance in developing extremity vein thrombosis (89.6% vs 68.8%, \( P < 0.05 \)), with positive pathergy test (54.5% vs 25.0%, \( P < 0.05 \)), and less predominance in developing CVT (7.8% vs 37.5%, \( P < 0.01 \)) and genital ulcers (68.8% vs 93.8%, \( P < 0.05 \) (Table 2).

Laboratory Examination

At the time of thrombosis development, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were significantly higher in 67.8% (59/87) and 96.2% (75/78) of patients, respectively. The mean ESR was 41 ± 33 mm/first hour and the mean CRP levels was 47 ± 51 mg/L.

Assays for anti-nuclear antibody (ANA), anti-double stranded DNA (anti-dsDNA) antibody, anti-extractable nuclear antigen (ENA) antibody, and anti-neutrophil cytoplasmic antibody (ANCA) were performed in all patients. Anti-dsDNA, anti-ENA antibody, and ANCA were all negative, while low titer of ANA was detected only in 7 patients. Human leukocyte antigen-B51 genotyping was positive in 11 out of 39 patients. Antiphospholipid antibodies including IgG type anti-cardiolipin antibody (ACL), IgG type anti-β2 glycosidoprotein 1 (β2GP1)

### Table 1. Main Types of Thrombosis in BD Patients

| Types of thrombosis        | No. of patients | %     |
|----------------------------|-----------------|-------|
| Extremity vein thrombosis  | 80              | 86.0  |
| Deep vein thrombosis       | 78              | 83.9  |
| Lower limbs                | 69              | 74.2  |
| Upper limbs                | 14              | 15.1  |
| Superficial thrombophlebitis| 4              | 4.3   |
| Vena cava thrombosis       | 28              | 30.1  |
| Superior vena cava         | 10              | 10.8  |
| Inferior vena cava         | 23              | 24.7  |
| Pulmonary thromboembolism  | 14              | 15.1  |
| Cerebral venous thrombosis | 12              | 12.9  |
| Intracardiac thrombosis    | 8               | 8.6   |
| Budd–Chiari syndrome       | 7               | 7.5   |
| Renal vein thrombosis      | 4               | 4.3   |
| Lower extremity artery thrombosis | 3 | 3.2 |
Treatment and Follow-Up

All patients received glucocorticosteroids and immunosuppressive agents. The initial glucocorticosteroids dosage was 10 mg to 60 mg/d of prednisone or equivalent dosage of other corticosteroids, with the average dose of 52 ± 11 mg. Thirteen patients had 1000 mg methylprednisolone pulse therapy for 3 days and then switched to oral prednisone 1 mg/kg/d and gradually tapered to 10 mg/d or less. In terms of immunosuppressant, cyclophosphamide was the most commonly used (83.7%, 77/92); others included thalidomide (n = 28), cycloporine (n = 12), tripterygium glycosides (n = 11), colchicine (n = 8), hydroxychloroquine (n = 7), methotrexate (n = 6), and azathioprine (n = 1). Forty-nine patients received two or more immunosuppressants. Anti-platelet agents and/or anticoagulants were used in 82 patients. Among them, 76 patients received anticoagulants, 1 patient received anti-platelet agents, and 5 patients received a combination of anti-platelet agents and anticoagulants. Eleven cases with multiple artery aneurysms were received neither anti-platelet agents nor anticoagulants. Eleven cases with multiple artery aneurysms were used in 82 patients. Among them, 76 patients received anticoagulants, 1 patient received anti-platelet agents, and 5 patients received a combination of anti-platelet agents and anticoagulants. Eleven cases with multiple artery aneurysms were received neither anti-platelet agents nor anticoagulants. Six patients with aneurysms and/or pseudoaneurysms and 2 patients with intracardiac thrombosis underwent surgical treatment.

After a median follow-up of 14 months (3–63 months), 89 patients improved as measured by decreased ESR and CRP levels (in 40 patients) and 4 patients died. One patient with DVT who was repeatedly hospitalized because of cardiac valvular disease complicated with infective endocarditis, and died from myocardial infarction despite of aggressive treatment of the underlying BD, anticoagulants and anti-infection therapy. One patient with vena cava thrombosis and multiple aneurysms received steroids and immunosuppressive agents and died from aneurysm rupture. One patient with Budd–Chiari syndrome died from hepatic failure, and another one complicated with septic shock and discontinued therapy.

DISCUSSION

Previous studies have demonstrated that vascular involvement is common in BD patients, affecting up to 40% of male patients; venous lesions have been reported to occur more frequently than arterial lesions.9,10 The prevalence of thrombosis in BD patients varies between 10% and 30%, in which multiple vessel beds are often affected.11 Fei et al12 have studied the prevalence and clinical characteristics of vascular involvement in Chinese BD patients from our center. Unlike Fei, our study focuses on clinical features of thrombosis in BD patients, including the location of DVT, disease activity on occurrence of thrombosis, and influence of gender on clinical course of BD patients with thrombosis. Based on our patient population, we demonstrated that the incidence of BD associated with thrombosis was 12.1% and it was more common in males (82.8%). Additionally, most of the patients had two or more sites of thrombosis. A male predominance of extremity vein thrombosis and positive pathergy test, and a female predominance of CVT and genital ulcers were noted. All of these patients exhibited active disease during the emergence of thrombotic events.

In the current study, the most common thrombotic manifestation was DVT in the extremities, and superficial thrombophlebitis occurred more often in male BD patients. As previously reported, DVT in the lower extremities often appears in the early stages of BD, the most common being venous thrombosis, accounting for 60% to 80% of all vascular involvement.9–11,13–14 The affected veins in descending order of frequency were the femoral, popliteal, and saphenous veins which could manifest as lower extremity pain, erythema with induration, edema and hyperpigmentation, intermittent

| TABLE 2. The Influence of Sex on the Clinical Course of BD Patients Complicated With Thrombosis |
|-----------------|-----------------|-----------------|
|                  | Total (n = 93)  | Male (n = 77)   | Female (n = 16) |
| Age at BD diagnosis (yrs, x ± s) | 32 ± 11         | 32 ± 10         | 35 ± 13         |
| Age at thrombotic events onset (yrs, x ± s) | 33 ± 10         | 32 ± 9          | 36 ± 13         |
| Clinical BD features                  |                 |                 |                 |
| Oral ulcer                             | 93 (100.0)      | 77 (100.0)      | 16 (100.0)      |
| Genital ulcer                          | 68 (73.1)       | 53 (68.8)       | 15 (93.8)       |
| Skin lesions                           | 67 (72.0)       | 57 (74.0)       | 10 (62.5)       |
| Pathergy reaction                      | 46 (49.5)       | 42 (54.5)       | 4 (25.0)        |
| Ocular lesions                         | 26 (28.0)       | 23 (29.9)       | 3 (18.8)        |
| Gastrointestinal involvement           | 9 (9.7)         | 7 (9.1)         | 2 (12.5)        |
| Type of thrombosis                     |                 |                 |                 |
| Extremity vein thrombosis              | 80 (86.0)       | 69 (89.6)       | 11 (68.8)       |
| Pulmonary thromboembolism              | 14 (15.1)       | 11 (14.3)       | 3 (18.8)        |
| Vena cava thrombosis                   | 28 (30.1)       | 26 (33.8)       | 2 (12.5)        |
| Intracardiac thrombosis                | 8 (8.6)         | 7 (9.1)         | 1 (6.3)         |
| Cerebral venous thrombosis             | 12 (12.9)       | 6 (7.8)         | 6 (37.5)        |

Compared with male.

BD = Behcet’s disease.

*P < 0.05.

**P < 0.01.
was either attached to the free wall or the septum, varied in size, and sometimes multiplied in one chamber or affected multiple chambers. After treatment, in two cases, the intracardiac thrombus disappeared and, in another two cases, remained stable after surgery without recurrence; the thrombus decreased in size in the other three patients.

The underlying mechanism of thrombosis in BD patients remains elusive. Multiple prothrombotic factors have been studied, but the results were controversial. According to previous reports, there was no significant correlation between antiphospholipid antibodies (APL) and thrombosis in BD. PT and partial thromboplastin time (PTT) also could not contribute to thrombosis in BD. Few reports indicated that deficiencies of protein C and protein S might be the risk factors for BD thrombosis. The main factor responsible for the increased frequency of thrombosis in BD is thought to be endothelial damage/activation. In addition, abnormal fibrinolysis and altered platelet function have also been associated with the development of thrombosis in BD. Genetic risk factors also a cause of thrombosis in BD. Factor V Leiden (FVL), prothrombin, and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms were reported to associate with thrombosis in BD. However, a systematic review and meta-analysis showed that FVL gene mutation (G1691A) was significantly associated with thrombosis in BD, but only relevant to Turkish patients. No significant association was found for the presence of prothrombin and MTHFR mutations and thrombosis in BD. Genetic predisposition may not be the same in different ethnic groups and geographical areas. Given the limitation of retrospective study, the genetic polymorphism information of our patients was not available.

The management of venous thrombosis in BD has remained controversial. In 2008, the European League Against Rheumatism published recommendations that endorsed the use of glucocorticoids and immunosuppressants (azathioprine, cyclophosphamide, and cyclosporine A) in the management of acute deep venous thrombosis in BD, while discouraging the use of antplatelet, anticoagulant, and antifibrinolytic agents, due to the fact that tight adhesions of a peripheral thrombosis to venous walls rarely results in emboli in the lungs. In addition, anticoagulants could increase the risk of rupturing aneurysms which could cause fatal bleeding. Recently, a French study including 807 BD patients found that the use of immunosuppressants significantly reduced the risk of recurrent DVT. In our study, aspirin and/or anticoagulants were used in thrombotic patients who did not have pulmonary artery aneurysms.

Our study is a retrospective analysis of a case series, which may bring some potential limitations. As our hospital is the nominated national referred center for complicated rheumatic diseases, which may result in more severe cases enrolled in our study, we cannot exclude the possibility of selection bias in this study population. Moreover, conclusions are only limited to a Chinese population and not especially generalizable to other populations.

In conclusion, vascular thrombosis is an important complication in BD patients and occurs more often in male patients. Venous thrombosis is more frequent than arterial thrombosis, and most of patients experienced multiple thrombosis. Active disease patients are prone to thrombosis, which suggest the key role of immunosuppressive therapy for the complication. Future studies exploring the mechanism of thrombosis and its link to inflammation may provide important insights in predicting which patients may be at a higher risk for thrombosis to improve outcomes.
REFERENCES

1. Davatchi F, Assaad-Khalil S, Calamia KT, et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol*. 2014;28:338–347.

2. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. *Lancet*. 1990;335:1078–1080.

3. Goodacre S, Stevenson M, Wailoo A, et al. How should we diagnose suspected deep-vein thrombosis? *QJM*. 2006;99:377–388.

4. Wang J, Guan W, Chen D, et al. The value of CTPA for diagnosing acute pulmonary thromboembolism and the ensuing right ventricular dysfunction. *Cell Biochem Biophys*. 2014;69:517–522.

5. Saposnik G, Barinagarrementeria F, Brown RD Jr et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011;42:1158–1192.

6. Asamov RE, Muminov ShM, Dadam’iants NG, et al. Diagnosis and treatment of inferior vena cava thrombosis. *Ross Akad Med Nauk*. 2010;10:59–63.

7. Adegboye VO, Ogunseyinde AO, Obojini MO, et al. Superior vena cava obstruction: diagnosis, management and outcome. *East Afr Med J*. 2008;85:129–136.

8. Egolium UO, Stover DG, Anthony R, et al. Intracardiac thrombus: diagnosis, complications and management. *Am J Med Sci*. 2013;345:391–395.

9. Kural-Seyahı E, Fresko İ, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. *Medicine* (Baltimore). 2003;82:60–76.

10. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet’s disease: an update. *Curr Opin Rheumatol*. 2011;23:24–31.

11. Gaffo AL. Thrombosis in vasculitis. *Best Pract Res Clin Rheumatol*. 2013;27:57–67.

12. Fei Y, Li X, Lin S, et al. Major vascular involvement in Behçet’s disease: a retrospective study of 796 patients. *Clin Rheumatol*. 2013;32:845–852.

13. Sarica-Kucukoglu R, Akdag-Kose A, Kayaball M, et al. Vascular involvement in Behçet’s disease: a retrospective analysis of 2319 cases. *Int J Dermatol*. 2006;45:919–921.

14. Düzgün N, Ateş A, Aydındüğt OT, et al. Characteristics of vascular involvement in Behçet’s disease. *Scand J Rheumatol*. 2006;35:65–68.

15. Seyahi E, Yurdakul S. Behçet’s syndrome and thrombosis. *Mediterr J Hematol Infect Dis*. 2011;3:e2011026.

16. Springer J, Villa-Forte A. Thrombosis in vasculitis. *Curr Opin Rheumatol*. 2013;25:19–25.

17. Hamuryuden V, Melikoglu M. Vascular involvement in Behçet’s syndrome. In: Yazici Y, Yazici H, eds. *Behçet’s Syndrome*. 1st ed. New York: Springer; 2010:115–134.

18. Aguier de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behçet’s disease: a systematic review. *J Neurol*. 2011;258:719–727.

19. Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Behçet’s disease. *Arthritis Rheum*. 2009;61:518–526.

20. Mogulkoc N, Burgess MI, Bishop PW. Intracardiac thrombus in Behçet’s disease: a systematic review. *Chest*. 2000;118:479–487.

21. Geri G, Wechsler B, ThiftHung du L, et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. *Medicine* (Baltimore). 2012;91:25–34.

22. Mader R, Ziv M, Adawi M, et al. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet’s disease. *J Rheumatol*. 1999;26:2404–2408.

23. Harman E, Sayarlıoglu M, Harman M, et al. The evaluation of coagulation parameters and vessel involvement in Behçet’s disease. A clinical experience of Behçet’s disease: study of 152 cases. *Acta Med Iran*. 2013;51:215–223.

24. Sengül N, Demirer S, Yerdel MA, et al. Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement. *World J Surg*. 2000;24:1584–1588.

25. Navarro S, Ricart JM, Medina P, et al. Activated protein C levels in Behçet’s disease and risk of venous thrombosis. *Br J Haematol*. 2004;126:550–556.

26. Kwon SR, Lim MJ, Park SG, et al. Decreased protein S activity is related to the disease activity of Behçet’s disease. *Rheumatol Int*. 2006;27:39–43.

27. Haznedaroğlu IC, Ozcebe OL, Ozdemir O, et al. Impaired haemostatic kinetics and endothelial function in Behçet’s disease. *J Intern Med*. 1996;240:181–187.

28. Chambers JC, Haskard DO, Koosner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet’s syndrome. *J Am Coll Cardiol*. 2001;37:517–520.

29. Ricart JM, Ramon LA, Vaya A, et al. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis. *Br J Haematol*. 2008;141:716–719.

30. Akar S, Ozcan MA, Ates H, et al. Circulated activated platelets and increased platelet reactivity in patients with Behçet’s disease. *Clin Appl Thromb Hemost*. 2006;12:451–457.

31. Chamorro AJ, Marcos M, Hernández-García I, et al. Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet’s disease: a systematic review and meta-analysis. *Autoimmun Rev*. 2013;12:607–616.

32. Hatri G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. *Ann Rheum Dis*. 2008;67:1656–1662.